Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma

Inclusion Criteria: * Persistent, or relapsed non-Hodgkin's lymphoma (NHL) (any histology) that is chemo-resistant (\< a partial response \[PR\]), subjects who have received \>= 3 prior chemotherapy regimens, or subjects with lymphomas that have a high relapse rate following autologous or syngeneic stem cell transplantation (transformed NHL, peripheral T-cell lymphoma \[PTCL\], mantle cell lymphoma, anaplastic lymphoma kinase \[ALK\]-negative anaplastic large cell lymphoma \[ALCL, alk neg\]), intermediate International Prognostic Index (IPI) or high risk IPI or subjects with a positive positron emission tomography (PET) scan prior to transplant, and otherwise eligible for transplantation with adequate end-organ function * Subjects that relapse within one year of diagnosis * Able to collect \>= 1.5 x 10\^6 CD34+/kg cell for transplantation * Absolute neutrophil count (ANC) \>= 1000 cells/mm\^3 and platelet count \>= 60 K when maintenance lenalidomide is started (day 100 post-transplant) * Subjects must have calculated creatinine clearance \>= 30 ml/min * Total bilirubin =\< 1.5 x upper limit of normal (ULN) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 x ULN * Subjects who are seropositive because of hepatitis B virus vaccine * Subjects must be willing to give written informed consent, and sign an institutionally approved consent form before perfor…